View source for 18454684. CHIMERIC ANTIGEN RECEPTORS THAT BIND PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA (PRAME)/HLA-A2 TO TREAT CANCER simplified abstract (Fred Hutchinson Cancer Center)

=CHIMERIC ANTIGEN RECEPTORS THAT BIND PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA (PRAME)/HLA-A2 TO TREAT CANCER=


==Organization Name==

[[:Category:Fred Hutchinson Cancer Center|Fred Hutchinson Cancer Center]]


[[Category:Fred Hutchinson Cancer Center]]

==Inventor(s)==

[[:Category:Soheil Meshinchi of Seattle WA (US)|Soheil Meshinchi of Seattle WA (US)]][[Category:Soheil Meshinchi of Seattle WA (US)]]

[[:Category:Danielle Kirkey of Seattle WA (US)|Danielle Kirkey of Seattle WA (US)]][[Category:Danielle Kirkey of Seattle WA (US)]]

[[:Category:Anisha Loeb of Seattle WA (US)|Anisha Loeb of Seattle WA (US)]][[Category:Anisha Loeb of Seattle WA (US)]]

[[:Category:Quy H. Le of Puyallup WA (US)|Quy H. Le of Puyallup WA (US)]][[Category:Quy H. Le of Puyallup WA (US)]]

==CHIMERIC ANTIGEN RECEPTORS THAT BIND PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA (PRAME)/HLA-A2 TO TREAT CANCER - A simplified explanation of the abstract==


This abstract first appeared for US patent application 18454684 titled 'CHIMERIC ANTIGEN RECEPTORS THAT BIND PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA (PRAME)/HLA-A2 TO TREAT CANCER

==Simplified Explanation==

The patent application discloses chimeric antigen receptors (CAR) that specifically bind to Preferentially Expressed Antigen in Melanoma (PRAME) ALY/HLA-A2, which can be used to treat PRAME/HLA-A2 expressing cancers such as certain forms of acute myeloid leukemia.

* The CAR binds to PRAME/HLA-A2, targeting cancer cells expressing this specific antigen.
* The technology can be applied to t(8;21), Inv(16), and KMT2A-r forms of acute myeloid leukemia.
* The innovation provides a targeted approach to cancer treatment, potentially improving efficacy and reducing side effects compared to traditional therapies.

== Potential Applications ==
The technology can be applied in the treatment of PRAME/HLA-A2 expressing cancers, particularly in certain forms of acute myeloid leukemia.

== Problems Solved ==
The technology addresses the need for targeted therapies in cancer treatment, specifically targeting cancer cells expressing PRAME/HLA-A2.

== Benefits ==
The use of CAR technology targeting PRAME/HLA-A2 can potentially improve treatment outcomes, reduce side effects, and provide a more targeted approach to cancer therapy.

== Potential Commercial Applications ==
The technology has potential applications in the development of CAR T-cell therapies for PRAME/HLA-A2 expressing cancers, which could be valuable in the biopharmaceutical industry.

== Possible Prior Art ==
Prior art may include other CAR technologies targeting specific antigens in cancer cells, as well as previous research on PRAME expression in melanoma and other cancers.

=== Unanswered Questions ===

== How does the CAR specifically target PRAME/HLA-A2 expressing cancer cells? ==
The mechanism by which the CAR binds to PRAME/HLA-A2 and distinguishes cancer cells from normal cells is not fully explained in the abstract.

== What are the potential challenges or limitations of using this technology in clinical settings? ==
The abstract does not address any potential obstacles or limitations that may arise when translating this technology from the laboratory to clinical applications.


==Original Abstract Submitted==

Chimeric antigen receptors (CAR) that bind Preferentially Expressed Antigen in Melanoma (PRAME) ALY(SEQ ID NO: 94)/HLA-A2 are disclosed. The CAR can be used to treat PRAME/HLA-A2 expressing cancers such as the t(8;21), Inv(16), and KMT2A-r forms of acute myeloid leukemia (AML).



[[Category:A61K35/17]]
[[Category:A61K38/21]]
[[Category:A61K39/00]]
[[Category:A61P35/02]]
[[Category:C07K14/74]]